Product Description
Regadenoson is an adenosine A(2A) receptor agonist approved for use as a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Regadenoson causes a rapid increase in coronary blood flow, which is sustained for a short duration. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20063904/)
Mechanisms of Action: ADRA2A Agonist
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States
Approved Indications: Generalized anxiety disorder
Known Adverse Events: Angina Pectoris | Chest Pain | Dizziness | Headache | Pain Unspecified | Dyspnea | Flushing
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, Greece, Italy, United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Coronary Artery Disease|Coronary Disease|Heart Transplant|Kawasaki Disease|Myocardial Ischemia
Phase 1: Generalized anxiety disorder|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Rapiscan PIP | P2 |
Recruiting |
Coronary Artery Disease|Myocardial Ischemia |
2026-12-01 |
|
| GE-262-001 | P2 |
Unknown Status |
Kawasaki Disease|Coronary Disease|Heart Transplant |
2025-07-04 |
|
| CTR20213200 | P1 |
Not yet recruiting |
Healthy Volunteers|Generalized anxiety disorder |
None |